192 related articles for article (PubMed ID: 2861866)
1. [Effect of carbidine on the dopamine and serotonin receptors of the central nervous system].
Zharkovskiĭ AM; Klassen NE; Zharkovskiĭ TA
Biull Eksp Biol Med; 1985 Jun; 99(6):700-2. PubMed ID: 2861866
[TBL] [Abstract][Full Text] [Related]
2. [Changes in the sensitivity of brain dopamine and serotonin receptors during the prolonged administration of carbidine].
Zharkovskiĭ AM; Chereshka KS; Zharkovskaia TA; Allikmets LKh
Biull Eksp Biol Med; 1985 Dec; 100(12):719-22. PubMed ID: 2866801
[TBL] [Abstract][Full Text] [Related]
3. [Effect of carbidine, sulpiride and haloperidol on levels of monoamines and their metabolites in the brain structures of rats].
Miroshnichenko II; Kudrin VS; Raevskiĭ KS
Farmakol Toksikol; 1988; 51(2):26-9. PubMed ID: 2897932
[TBL] [Abstract][Full Text] [Related]
4. [Effect of the atypical neuroleptics carbidine and sulpiride on dopamine biosynthesis in the synaptosomes of the nucleus accumbens septi in rats].
Kudrin VS; Hetey L; Morgenshtern R; Raevskiĭ KS; Olssner W
Farmakol Toksikol; 1987; 50(2):16-20. PubMed ID: 2884129
[TBL] [Abstract][Full Text] [Related]
5. Antipsychotic drug effects on dopamine and serotonin receptors: in vitro binding and in vivo turnover studies.
Bacopoulos NG
J Pharmacol Exp Ther; 1981 Dec; 219(3):708-14. PubMed ID: 6170752
[TBL] [Abstract][Full Text] [Related]
6. [Effect of the atypical neuroleptics karbidin and sulpiride on the synaptosomal tyrosine hydroxylase of the corpus striatum of rats].
Meos AA; Kudrin VS; Raevskiĭ KS
Biull Eksp Biol Med; 1984 Sep; 98(9):305-8. PubMed ID: 6148973
[TBL] [Abstract][Full Text] [Related]
7. Changes in apomorphine-induced stereotypy as a result of subacute neuroleptic treatment correlates with increased D-2 receptors, but not with increases in D-1 receptors.
Fleminger S; Rupniak NM; Hall MD; Jenner P; Marsden CD
Biochem Pharmacol; 1983 Oct; 32(19):2921-7. PubMed ID: 6138043
[TBL] [Abstract][Full Text] [Related]
8. Neuroleptic activity of the 5-aryltetrahydro-gamma-carboline series. Conformational requirements for interaction with central dopamine receptors.
Harbert CA; Plattner JJ; Welch WM; Weissman A; Koe BK
Mol Pharmacol; 1980 Jan; 17(1):38-42. PubMed ID: 6104285
[No Abstract] [Full Text] [Related]
9. [Role of serotonin and dopamine receptors in the mechanism of action of haloperidol and pirenperone].
Maĭmets MO; Vasar EE; Nurk AM; Allikmets LKh
Farmakol Toksikol; 1985; 48(2):15-8. PubMed ID: 3996566
[TBL] [Abstract][Full Text] [Related]
10. [Effect of carbidine on dopamine turnover in the rat corpus striatum].
Malikova LA; Arefolov VA
Farmakol Toksikol; 1980; 43(3):310-3. PubMed ID: 6108865
[TBL] [Abstract][Full Text] [Related]
11. [Change in dopamine and serotonin receptor sensitivity following chronic chlorpromazine administration].
Zharkovskiĭ AM; Riago LK; Arro AG
Zh Vyssh Nerv Deiat Im I P Pavlova; 1980; 30(1):165-8. PubMed ID: 7189932
[TBL] [Abstract][Full Text] [Related]
12. Differential alteration of striatal D-1 and D-2 receptors induced by the long-term administration of haloperidol, sulpiride or clozapine to rats.
Jenner P; Rupniak NM; Marsden CD
Psychopharmacology Suppl; 1985; 2():174-81. PubMed ID: 3159009
[TBL] [Abstract][Full Text] [Related]
13. The involvement of serotonin in the mechanism of central action of apomorphine.
Grabowska M
Pol J Pharmacol Pharm; 1976; 28(4):389-94. PubMed ID: 790347
[TBL] [Abstract][Full Text] [Related]
14. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
Millan MJ; Gobert A; Newman-Tancredi A; Audinot V; Lejeune F; Rivet JM; Cussac D; Nicolas JP; Muller O; Lavielle G
J Pharmacol Exp Ther; 1998 Sep; 286(3):1341-55. PubMed ID: 9732398
[TBL] [Abstract][Full Text] [Related]
15. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
Marshall AM; Mishra RK
Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
[No Abstract] [Full Text] [Related]
16. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
17. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
18. Definition of the in-vivo accumulation of [3H]spiperone in brain using haloperidol and sulpiride to determine functional dopamine receptor occupation.
Chivers JK; Reavill C; Jenner P; Marsden CD
J Pharm Pharmacol; 1988 Sep; 40(9):613-9. PubMed ID: 2907027
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
20. Long-term adaptive changes in striatal dopamine function in response to chronic neuroleptic intake in rats.
Jenner P; Kerwin R; Rupniak NM; Murugaiah K; Hall MD; Fleminger S; Marsden CD
J Neural Transm Suppl; 1983; 18():205-12. PubMed ID: 6135741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
